Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia.
Eur Rev Med Pharmacol Sci. 2021 Jul;25(14):4841-4853. doi: 10.26355/eurrev_202107_26398.
To investigate the role of Convalescent Plasma (CP) in reducing mortality of COVID-19 patients.
A systematic literature search was conducted from PubMed, Embase, Medrxiv, and Google Scholar from April and finalized in December 2020 using the following terms: covid-19, convalescent plasma, cp, ccp, copla. The studies were screened, extracted, and evaluated by two authors independently. Comparative retrospective or prospective studies with a control group were included. Mortality was defined as the outcome of interest. Research articles not published in the English language, not available in full text, review articles, no measured outcome of interest were excluded from this study.
Eighteen studies were included in this meta-analysis. There were 5658 patients with 2092 patients treated with CP and 3536 patients as a control group. Forest plot showed CP use was associated with decreased mortality with OR = 0.64 (95% CI 0.49 to 0.84, p<0.001) and heterogeneity (I2)= 27.62%. Few patients experienced an adverse event, but no fatal case was reported.
Convalescent plasma is effective in reducing mortality of severe and critical COVID-19 with tolerable adverse effects.
研究恢复期血浆（CP）在降低 COVID-19 患者死亡率中的作用。
从 PubMed、Embase、Medrxiv 和 Google Scholar 中进行了系统的文献检索，检索时间为 2020 年 4 月至 12 月，使用的检索词如下：covid-19、恢复期血浆、cp、ccp、copla。由两名作者独立筛选、提取和评估研究。纳入了有对照组的比较回顾性或前瞻性研究。死亡率被定义为研究的主要结局。本研究排除了未用英文发表、无法获取全文、综述文章以及未测量主要结局的研究。
共有 18 项研究纳入本荟萃分析。共有 5658 例患者，其中 2092 例患者接受 CP 治疗，3536 例患者作为对照组。森林图显示 CP 的使用与死亡率降低相关，OR = 0.64（95% CI 0.49 至 0.84，p<0.001），且存在异质性（I2）= 27.62%。少数患者出现不良反应，但未报告致命病例。
恢复期血浆在降低严重和危重新冠肺炎患者的死亡率方面是有效的，且不良反应可耐受。
